Actavis gets $70B-plus in orders for new bond offering; Salix sales plummet after inventory snafu;

@FiercePharma: IYCMI yesterday: Medicare urged to crack down on antipsychotic scripts for dementia sufferers. Report | Follow @FiercePharma

@EricPFierce: FDA unloads another 14 observations on Hospira Vizag India plant, further delaying its opening. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: To avoid becoming deal bait, Mylan CEO may have to make another big buy. News | Follow @CarlyHFierce

> Actavis' ($ACT) new bond offering is a hot prospect, with orders reportedly reaching $70 billion to $90 billion for an intended sale of $22 billion; proceeds will be used to help fund the company's $66 billion Allergan buyout. Report

> Salix Pharmaceuticals ($SLXP), set to be acquired by Valeant, posted a fourth-quarter loss on a steep decline in revenue, to $13 million from $238 million the prior year; the loss was expected after the company announced a previously unreported and large buildup in inventory at the wholesale level. Report

> At its Wednesday annual meeting, Roche ($RHHBY) added two new board members, the former CEO of Wyeth, Bernard Poussot, and Yale University genomics professor Richard Lifton. Release

> Two members of Congress have joined other government officials challenging Amphastar Pharmaceuticals on its rising price for the overdose-fighting drug naloxone. Report

> France-based Ipsen posted 2014 sales of €1.27 billion ($1.42 billion), a 6% increase, which fueled an 8.6% increase in profits, to €154.5 million. Report

> Sanofi's ($SNY) animal health company Merial wrapped up its purchase of two horse products, the joint injection Legend and neurological treatment Marquis, from Bayer HealthCare. Report

Medical Device News

@FierceMedDev: UPDATED with interview: FDA approves Actavis intrauterine device to prevent pregnancy. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Boston Sci to acquire Endo's men's health devices for $1.6B. Story | Follow @VarunSaxena2

> Nevro appoints former JJDC head to board as it awaits anticipated FDA approval. More

> In loss for Medtronic, appeals court overturns $102M owed by NuVasive for patent infringement. Story

> Siemens Healthcare accused of faking contracts in China. Report

Biotech News

@FierceBiotech: Bullish ex-Elan chief plots a $43M buy-in for upstart Serenus. Article | Follow @FierceBiotech

@JohnCFierce: Remember when the NVCA wailed over the unsustainable VC model in biotech, the FDA's fossilized review process? Ah, the old days... in 2012. | Follow @JohnCFierce

@DamianFierce: German Merck refers to itself as "Merck KGaA, Darmstadt, Germany" on every reference. We get it. You're German. More | Follow @DamianFierce

> Boehringer takes pole position with its 'breakthrough' anti-anticoagulant. Article

> Ambitious cancer R&D plans may explain Merck KGaA cutbacks. Item

> J&J picks the inaugural class for its Bay Area biotech incubator. Report

Biotech Research News

> Canadian researchers study a new mechanism of action for cancer metastasis. More

> Scripps investigators ID a key player in disarming chemotherapy. Report

> Glioblastoma project IDs a new approach to brain cancer and understanding EGFR. Article

> Researchers add insights to IL-37's anti-inflammatory potential. More

> Mount Sinai preclinical program flags a potential drug strategy for MS. Story

Pharma Manufacturing News

> Hospitals say Roche supply chain move is affecting patient care. Item

> Pfizer shuttering vitamin C plant in California, 70 workers out of jobs. Report

> Hospira's new India plant again faulted by the FDA. Story

> Companies strike trans-Pacific manufacturing and development agreement. More

> G&W Laboratories buying Teva plant after picking up one from Actavis. Article

Pharma Asia News

> Sun Pharma buys GSK's Tasmania opiates business to expand pain offerings. More

> Gilead moves from Japan to India lining up hep C, HIV licensing deals. Story

> Singapore's TauRx notes Alzheimer's candidate journal publication, but buzz eludes. Article

> Takeda confirms eyeing opportunities in India, elsewhere, in vaccine space. News

> Deadly flu outbreak in Hong Kong gathers pace, prompting vaccination push. More

And Finally... Most doctors give in to requests by parents to avoid or delay vaccinations, a survey found. Report

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.